Previous 10 | Next 10 |
The following slide deck was published by Kodiak Sciences Inc. in conjunction with this event. For further details see: Kodiak Sciences (KOD) Presents At 39th Annual J.P. Morgan Healthcare Conference - Slideshow
2020 was a year of immense adversity and contrast, as stocks bounced back sharply from a pandemic-induced bear market. Biotechs play a pivotal role in managing down the pandemic as vaccine production ramps higher. January to provide further insights on multiple additional vaccine tria...
Kodiak Sciences to Present at the J.P. Morgan Healthcare Conference PR Newswire PALO ALTO, Calif. , Jan. 5, 2021 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transfor...
In my 2020 outlook, which was pre-coronavirus, I argued the case for buying small and microcap medical stocks that were priced for "non-success". This approach worked in 2020. My 2020 themes were gene therapy, targeted oncologics, and less invasive surgery. For 2021, I add SARS CoV-2 ...
Small caps finally record a new high after two years and turn positive for the year. Vaccine progress is raising expectations of a more robust and durable economic recovery in 2021, driving a rotation into lagging segments and economically sensitive sectors. Small caps can witness...
Kodiak Sciences Announces Closing of $645.0 Million Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares PR Newswire PALO ALTO, Calif., Nov. 20, 2020 PALO ALTO, Calif. , Nov. 20, 2020 /PRNewswire/ -- Kod...
Gainers: Phoenix Tree (DNK) +91%.Naked Brand (NAKD) +64%.Kazia Therapeutics (KZIA) +32%.Micro Focus International (MFGP) +32%.BELLUS Health (BLU) +31%.InnSuites Hospitality Trust (IHT) +27%.FuelCell Energy (FCEL) +27%.Ashford Hospitality Trust (AHT) +24%.CIIG Merger (CIIC) ...
Kodiak Sciences Announces Pricing of $560.9 Million Public Offering of Common Stock PR Newswire PALO ALTO, Calif., Nov. 17, 2020 PALO ALTO, Calif. , Nov. 17, 2020 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to res...
The hot-handed biotech is selling $400M of common stock, with underwriter greenshoe for up to another $60M worth of shares.Kodiak (KOD) is up a modest 400% on a year-over-year basis, now sporting a market cap above $5B.Shares are down 5.6% after hours.Source: Press Release...
Kodiak Sciences Completes Enrollment of DAZZLE Phase 2b/3 Pivotal Study of KSI-301 in Patients with Wet Age-Related Macular Degeneration − On track for DAZZLE primary endpoint last patient last visit in late 2021 and topline results in early 2022 − Over 550 pat...
News, Short Squeeze, Breakout and More Instantly...
Kodiak Sciences to Present at Upcoming Investor and Clinical Conferences PR Newswire PALO ALTO, Calif. , May 29, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transfor...
Kodiak Sciences Announces Recent Business Highlights and First Quarter 2024 Financial Results PR Newswire PALO ALTO, Calif. , May 15, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported business highlights and financial results for the qu...
Kodiak Sciences Announces Treatment of First Patients in Phase 3 GLOW2 Study of Tarcocimab Tedromer in Diabetic Retinopathy PR Newswire PALO ALTO, Calif. , May 13, 2024 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to r...